|
1.
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality, and prevalence across five
continents: defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar
|
|
2.
|
Parkin DM, Bray FI and Devesa SS: Cancer
burden in the year 2000. The global picture. Eur J Cancer.
37:S4–66. 2001.PubMed/NCBI
|
|
3.
|
Sant M, Allemani C, Santaquilani M, Knijn
A, Marchesi F and Capocaccia R; EUROCARE Working Group: EUROCARE-4.
Survival of cancer patients diagnosed in 1995–1999 Results and
commentary. Eur J Cancer. 45:931–991. 2009.
|
|
4.
|
Xing D, Tan W and Lin D: Genetic
polymorphisms and susceptibility to esophageal cancer among Chinese
population (review). Oncol Rep. 10:1615–1623. 2003.PubMed/NCBI
|
|
5.
|
Stoner GD and Gupta A: Etiology and
chemoprevention of esophageal squamous cell carcinoma.
Carcinogenesis. 22:1737–1746. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Besharat S, Jabbari A, Semnani S, Keshtkar
A and Marjani J: Inoperable esophageal cancer and outcome of
palliative care. World J Gastroenterol. 14:3725–3728. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Alibakhshi A, Aminian A, Mirsharifi R,
Jahangiri Y, Dashti H and Karimian F: The effect of age on the
outcome of esophageal cancer surgery. Ann Thorac Med. 4:71–74.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Wei WT, Chen H, Ni ZL, Liu HB, Tong HF,
Fan L, Liu A, Qiu MX, Liu DL, Guo HC, Wang ZH and Lin SZ: Antitumor
and apoptosis-promoting properties of emodin, an anthraquinone
derivative from Rheum officinale Baill, against pancreatic
cancer in mice via inhibition of Akt activation. Int J Oncol.
39:1381–1390. 2011.PubMed/NCBI
|
|
9.
|
Ma YS, Weng SW, Lin MW, Lu CC, Chiang JH,
Yang JS, Lai KC, Lin JP, Tang NY, Lin JG and Chung JG: Antitumor
effects of emodin on LS1034 human colon cancer cells in
vitro and in vivo: roles of apoptotic cell death and
LS1034 tumor xenografts model. Food Chem Toxicol. 50:1271–1278.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Kimura Y, Kubo M, Tani T, Arichi S,
Ohminami H and Okuda H: Studies on Scutellariae radix. III
Effects on lipid metabolism in serum, liver and fat cells of rats.
Chem Pharm Bull. 29:2308–2312. 1981.
|
|
11.
|
Lin CC and Shieh DE: The anti-inflammatory
activity of Scutellaria rivularis extracts and its active
components, baicalin, baicalein and wogonin. Am J Chin Med.
24:31–36. 1996.
|
|
12.
|
Lu Y, Joerger R and Wu C: Study of the
chemical composition and antimicrobial activities of ethanolic
extracts from roots of Scutellaria baicalensis Georgi. J
Agric Food Chem. 59:10934–10942. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Miocinovic R, McCabe NP, Keck RW, Jankun
J, Hampton JA and Selman SH: In vivo and in vitro
effect of baicalein on human prostate cancer cells. Int J Oncol.
26:241–246. 2005.
|
|
14.
|
Ma Z, Otsuyama K, Liu S, Abroun S,
Ishikawa H, Tsuyama N, Obata M, Li FJ, Zheng X, Maki Y, Miyamoto K
and Kawano MM: Baicalein, a component of Scutellariae radix
from Huang-Lian- Jie-Du-Tang (HLJDT), leads to suppression of
proliferation and induction of apoptosis in human myeloma cells.
Blood. 105:3312–3318. 2005.PubMed/NCBI
|
|
15.
|
Chen CH, Huang LL, Huang CC, Lin CC, Lee Y
and Lu FJ: Baicalein, a novel apoptotic agent for hepatoma cell
lines: a potential medicine for hepatoma. Nutr Cancer. 38:287–295.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Lee HZ, Leung HW, Lai MY and Wu CH:
Baicalein induced cell cycle arrest and apoptosis in human lung
squamous carcinoma CH27 cells. Anticancer Res. 25:959–964.
2005.PubMed/NCBI
|
|
17.
|
Chao JI, Su WC and Liu HF: Baicalein
induces cancer cell death and proliferation retardation by the
inhibition of CDC2 kinase and survivin associated with opposite
role of p38 mitogen-activated protein kinase and AKT. Mol Cancer
Ther. 6:3039–3048. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Shieh DE, Cheng HY, Yen MH, Chiang LC and
Lin CC: Baicalin-induced apoptosis is mediated by Bcl-2-dependent,
but not p53-dependent, pathway in human leukemia cell lines. Am J
Chin Med. 34:245–261. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Lu HF, Hsueh SC, Ho YT, Kao MC, Yang JS,
Chiu TH, Huamg SY, Lin CC and Chung JG: ROS mediates
baicalin-induced apoptosis in human promyelocytic leukemia HL-60
cells through the expression of the Gadd153 and
mitochondrial-dependent pathway. Anticancer Res. 27:117–125.
2007.
|
|
20.
|
Kuo HM, Tsai HC, Lin YL, Yang JS, Huang
AC, Yang MD, Hsu SC, Chung MC, Gibson Wood W and Chung JG:
Mitochondrial-dependent caspase activation pathway is involved in
baicalein-induced apoptosis in human hepatoma J5 cells. Int J
Oncol. 35:717–724. 2009.PubMed/NCBI
|
|
21.
|
Altomare DA and Testa JR: Perturbations of
the AKT signaling pathway in human cancer. Oncogene. 24:7455–7464.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Tokunaga E, Oki E, Egashira A, Sadanaga N,
Morita M, Kakeji Y and Maehara Y: Deregulation of the Akt pathway
in human cancer. Curr Cancer Drug Targets. 8:27–36. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Li H, Gao Q, Guo L and Lu SH: The
PTEN/PI3K/Akt pathway regulates stem-like cells in primary
esophageal carcinoma cells. Cancer Biol Ther. 11:950–958. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Li B, Cheung PY, Wang X, Tsao SW, Ling MT,
Wong YC and Cheung AL: Id-1 activation of PI3K/Akt/NFkappaB
signaling pathway and its significance in promoting survival of
esophageal cancer cells. Carcinogenesis. 28:2313–2320. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Li B, Tsao SW, Li YY, Wang X, Ling MT,
Wong YC, He QY and Cheung AL: Id-1 promotes tumorigenicity and
metastasis of human esophageal cancer cells through activation of
PI3K/AKT signaling pathway. Int J Cancer. 125:2576–2585. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Zhao H, Yang J, Fan T, Li S and Ren X:
RhoE functions as a tumor suppressor in esophageal squamous cell
carcinoma and modulates the PTEN/PI3K/Akt signaling pathway. Tumour
Biol. 33:1363–1374. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Agarwal S, Achari C, Praveen D, Roy KR,
Reddy GV and Reddanna P: Inhibition of 12-LOX and COX-2 reduces the
proliferation of human epidermoid carcinoma cells (A431) by
modulating the ERK and PI3K-Akt signalling pathways. Exp Dermatol.
18:939–946. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Lowry OH, Rosebrough NJ, Farr AL and
Randall RJ: Protein measurement with the Folin phenol reagent. J
Biol Chem. 193:265–275. 1951.PubMed/NCBI
|
|
29.
|
Song L, Xiong H, Li J, Liao W, Wang L, Wu
J and Li M: Sphingosine kinase-1 enhances resistance to apoptosis
through activation of PI3K/Akt/NF-κB pathway in human non-small
cell lung cancer. Clin Cancer Res. 17:1839–1849. 2011.PubMed/NCBI
|
|
30.
|
Tsuruta F, Masuyama N and Gotoh Y: The
phosphatidylinositol 3-kinase (PI3K)-Akt pathway suppresses Bax
translocation to mitochondria. J Biol Chem. 277:14040–14047. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Datta SR, Dudek H, Tao X, Masters S, Fu H,
Gotoh Y and Greenberg ME: Akt phosphorylation of BAD couples
survival signals to the cell-intrinsic death machinery. Cell.
91:231–241. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Cardone MH, Roy N, Stennicke HR, Salvesen
GS, Franke TF, Stanbridge E, Frisch S and Reed JC: Regulation of
cell death protease caspase-9 by phosphorylation. Science.
282:1318–1321. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Shen HM and Tergaonkar V: NFκB signaling
in carcinogenesis and as a potential molecular target for cancer
therapy. Apoptosis. 14:348–363. 2009.
|
|
34.
|
Tian F, Fan T, Jiang Y, Zhang X and Wang
X: A small interfering RNA targeting NF-κB p65 alone or combined
with 5-FU inhibits growth of esophageal squamous cell carcinoma in
nude mice. Pathol Res Pract. 208:32–38. 2012.
|
|
35.
|
Tian F, Zang WD, Hou WH, Liu HT and Xue
LX: Nuclear factor-kB signaling pathway constitutively activated in
esophageal squamous cell carcinoma cell lines and inhibition of
growth of cells by small interfering RNA. Acta Biochim Biophys Sin.
38:318–326. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Su C, Chen Z, Luo H, Su Y, Liu W, Cai L,
Wang T, Lei Y and Zhong B: Different patterns of NF-κB and Notch1
signaling contribute to tumor-induced lymphangiogenesis of
esophageal squamous cell carcinoma. J Exp Clin Cancer Res.
30:852011.
|
|
37.
|
Madrid LV, Mayo MW, Reuther JY and Baldwin
AS Jr: Akt stimulates the transactivation potential of the RelA/p65
Subunit of NF-kappa B through utilization of the Ikappa B kinase
and activation of the mitogen-activated protein kinase p38. J Biol
Chem. 276:18934–18940. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Vermeulen L, Vanden Berghe W and Haegeman
G: Regulation of NF-κB transcriptional activity. Cancer Treat Res.
130:89–102. 2006.
|
|
39.
|
Fingar DC, Richardson CJ, Tee AR, Cheatham
L, Tsou C and Blenis J: mTOR controls cell cycle progression
through its cell growth effectors S6K1 and 4E-BP1/eukaryotic
translation initiation factor 4E. Mol Cell Biol. 24:200–216. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Fingar DC, Salama S, Tsou C, Harlow E and
Blenis J: Mammalian cell size is controlled by mTOR and its
downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 16:1472–1487.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Bjornsti MA and Houghton PJ: The TOR
pathway: a target for cancer therapy. Nat Rev Cancer. 4:335–348.
2004. View
Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Xu G, Zhang W, Bertram P, Zheng XF and
McLeod H: Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR
pathway in common human tumors. Int J Oncol. 24:893–900.
2004.PubMed/NCBI
|
|
43.
|
Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue
P, Fu H and Khuri FR: Activation of Akt and eIF4E survival pathways
by rapamycin-mediated mammalian target of rapamycin inhibition.
Cancer Res. 65:7052–7058. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Hou G, Xue L, Lu Z, Fan T, Tian F and Xue
Y: An activated mTOR/p70S6K signaling pathway in esophageal
squamous cell carcinoma cell lines and inhibition of the pathway by
rapamycin and siRNA against mTOR. Cancer Lett. 253:236–248. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Chang F, Lee JT, Navolanic PM, Steelman
LS, Shelton JG, Blalock WL, Franklin RA and McCubrey JA:
Involvement of PI3K/Akt pathway in cell cycle progression,
apoptosis, and neoplastic transformation: a target for cancer
chemotherapy. Leukemia. 17:590–603. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Hengartner MO: The biochemistry of
apoptosis. Nature. 407:770–776. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
47.
|
Orrenius S: Mitochondrial regulation of
apoptotic cell death. Toxicol Lett. 149:19–23. 2004. View Article : Google Scholar : PubMed/NCBI
|
